Dual Antiplatelet Therapy Versus Alteplase for Mild Stroke with Admission NIHSS Score 0–3 Versus 4–5: A Secondary Analysis of the ARAMIS Randomized Trial
CNS Drugs · 2025-10 · 39 (10) · 1037-1046
DOI: 10.1007/s40263-025-01211-6 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CNS Drugs, online erschienen am 04.08.2025. Verfasst von Zhao-Xia Fei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenhe District, Shenyang, 110016, China. Hauptthemen laut MEDLINE: Tissue Plasminogen Activator, Platelet Aggregation Inhibitors, Fibrinolytic Agents, Ischemic Stroke. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: the Science and Technology Project Plan of Liaoning Province.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: The ARAMIS trial demonstrated the non-inferiority of dual antiplatelet therapy (DAPT) to alteplase in patients with minor nondisabling ischemic stroke. We aimed to investigate whether the degree of neurological deficit can affect the benefit of DAPT versus alteplase. METHODS: On the basis of the as-treated analysis set, eligible patients with acute minor nondisabling stroke were divided into NIHSS 0-3 and NIHSS 4-5 groups, which was further subdivided into DAPT and alteplase groups. The primary outcome was excellent functional outcome, defined as a mRS score of 0-1 at 90 days, and the safety outcome was symptomatic intracerebral hemorrhage (sICH). RESULTS: A total of 719 patients were enrolled, including 585 in the NIHSS 0-3 group and 134 in the NIHSS 4-5 group. In the NIHSS score 0-3 group, the proportion of patients with mRS of 0-1 at 90 days was 95.5% (277/290) in the DAPT group and 92.2% (272/295) in the alteplase group. In the NIHSS score 4-5 group, the proportion of patients with mRS of 0 or 1 at 90 days was 82.7% (43/52) in the DAPT group and 90.2 % (74/82) in the alteplase group. A significant interaction effect was identified between the baseline NIHSS and treatment for the primary outcome (P = 0.048). There was no patient with sICH in the DAPT group. In the alteplase group, there were three and one patients with sICH in the NIHSS score 0-3 group and 4-5 group, respectively. CONCLUSIONS: Among patients with minor nondisabling acute ischemic stroke presenting within 4.5 h of symptom onset, the benefit of DAPT versus alteplase may be affected by the degree of neurological deficit on admission. DAPT may be favored in patients with a mild neurologic deficit, while alteplase is favored in patients with a higher degree of neurologic deficit. Trial Registration ClinicalTrials.gov Identifier: NCT03661411.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenhe District, Shenyang, 110016, China.
- Neurology, Radiology, Boston Medical Center, Boston, MA, USA.
- Department of Neurology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenhe District, Shenyang, 110016, China. chszh@aliyun.com.
ORCID-Profile: Hui-Sheng Chen
Förderung
- the Science and Technology Project Plan of Liaoning Province
Zitieren
APA
Fei, Z. X., Yin, Y., Cui, Y., Nguyen, T. N., & Chen, H. S. (2025). Dual Antiplatelet Therapy Versus Alteplase for Mild Stroke with Admission NIHSS Score 0–3 Versus 4–5: A Secondary Analysis of the ARAMIS Randomized Trial. CNS Drugs, 39(10), 1037-1046. https://doi.org/10.1007/s40263-025-01211-6
Vancouver
Fei ZX, Yin Y, Cui Y, Nguyen TN, Chen HS. Dual Antiplatelet Therapy Versus Alteplase for Mild Stroke with Admission NIHSS Score 0–3 Versus 4–5: A Secondary Analysis of the ARAMIS Randomized Trial. CNS Drugs. 2025;39(10):1037-1046. doi:10.1007/s40263-025-01211-6
BibTeX
@article{Fei2025,
author = {Fei, Zhao-Xia and Yin, Yue and Cui, Yu and Nguyen, Thanh N and Chen, Hui-Sheng},
title = {Dual Antiplatelet Therapy Versus Alteplase for Mild Stroke with Admission NIHSS Score 0–3 Versus 4–5: A Secondary Analysis of the ARAMIS Randomized Trial},
journal = {CNS Drugs},
year = {2025},
volume = {39},
number = {10},
pages = {1037--1046},
doi = {10.1007/s40263-025-01211-6}
}
EUVIMED